Limited by the technology available at onset, only some patients were tested for anti-phospholipase A2 receptor (PLA2R) antibodies; positive rates were 66.7% (2/3) in the associated MN group, 0.0% (0/3) in the + ANCA group, and 0.0% (0/2) in the anti-GBM GN group. Here, PLA2R1 is linked to glioblastoma.